Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells

Sarah A Holstein, Huaxiang Tong, Raymond J. Hohl

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Thalidomide has emerged as an effective agent for treating multiple myeloma, however the precise mechanism of action remains unknown. Agents known to target the isoprenoid biosynthetic pathway (IBP) can have cytotoxic effects in myeloma cells. The interactions between thalidomide and IBP inhibitors in human multiple myeloma cells were evaluated. Enhanced cytotoxicity and induction of apoptosis were observed in RPMI-8226 cells. Examination of intracellular levels of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) revealed a wide variance in basal levels and response to IBP inhibitors. These findings provide a mechanism for the differential sensitivity of myeloma cells to pharmacologic manipulation of the IBP.

Original languageEnglish (US)
Pages (from-to)344-351
Number of pages8
JournalLeukemia Research
Volume34
Issue number3
DOIs
StatePublished - Mar 1 2010

Fingerprint

Thalidomide
Biosynthetic Pathways
Terpenes
Multiple Myeloma
Apoptosis

Keywords

  • Farnesyl pyrophosphate
  • Geranylgeranyl pyrophosphate
  • Isoprenoid
  • Lovastatin
  • Myeloma
  • Thalidomide
  • Zoledronic acid

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. / Holstein, Sarah A; Tong, Huaxiang; Hohl, Raymond J.

In: Leukemia Research, Vol. 34, No. 3, 01.03.2010, p. 344-351.

Research output: Contribution to journalArticle

@article{15a191524ce14cd78e7a146aeef2e349,
title = "Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells",
abstract = "Thalidomide has emerged as an effective agent for treating multiple myeloma, however the precise mechanism of action remains unknown. Agents known to target the isoprenoid biosynthetic pathway (IBP) can have cytotoxic effects in myeloma cells. The interactions between thalidomide and IBP inhibitors in human multiple myeloma cells were evaluated. Enhanced cytotoxicity and induction of apoptosis were observed in RPMI-8226 cells. Examination of intracellular levels of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) revealed a wide variance in basal levels and response to IBP inhibitors. These findings provide a mechanism for the differential sensitivity of myeloma cells to pharmacologic manipulation of the IBP.",
keywords = "Farnesyl pyrophosphate, Geranylgeranyl pyrophosphate, Isoprenoid, Lovastatin, Myeloma, Thalidomide, Zoledronic acid",
author = "Holstein, {Sarah A} and Huaxiang Tong and Hohl, {Raymond J.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/j.leukres.2009.06.035",
language = "English (US)",
volume = "34",
pages = "344--351",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells

AU - Holstein, Sarah A

AU - Tong, Huaxiang

AU - Hohl, Raymond J.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Thalidomide has emerged as an effective agent for treating multiple myeloma, however the precise mechanism of action remains unknown. Agents known to target the isoprenoid biosynthetic pathway (IBP) can have cytotoxic effects in myeloma cells. The interactions between thalidomide and IBP inhibitors in human multiple myeloma cells were evaluated. Enhanced cytotoxicity and induction of apoptosis were observed in RPMI-8226 cells. Examination of intracellular levels of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) revealed a wide variance in basal levels and response to IBP inhibitors. These findings provide a mechanism for the differential sensitivity of myeloma cells to pharmacologic manipulation of the IBP.

AB - Thalidomide has emerged as an effective agent for treating multiple myeloma, however the precise mechanism of action remains unknown. Agents known to target the isoprenoid biosynthetic pathway (IBP) can have cytotoxic effects in myeloma cells. The interactions between thalidomide and IBP inhibitors in human multiple myeloma cells were evaluated. Enhanced cytotoxicity and induction of apoptosis were observed in RPMI-8226 cells. Examination of intracellular levels of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) revealed a wide variance in basal levels and response to IBP inhibitors. These findings provide a mechanism for the differential sensitivity of myeloma cells to pharmacologic manipulation of the IBP.

KW - Farnesyl pyrophosphate

KW - Geranylgeranyl pyrophosphate

KW - Isoprenoid

KW - Lovastatin

KW - Myeloma

KW - Thalidomide

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=77649182629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649182629&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2009.06.035

DO - 10.1016/j.leukres.2009.06.035

M3 - Article

VL - 34

SP - 344

EP - 351

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 3

ER -